Marek Poszepczynski

Marek Poszepczynski is a biotechnology and life sciences investment professional who previously served as the Lead Investment Manager at SV Health Managers LLP. Prior to assuming this leadership position, he worked as an investment analyst and consultant from 2014 to 2017. During his tenure managing the International Biotechnology Trust, he oversaw a portfolio representing approximately £258 million to £300 million in total assets. Under his management, the trust's portfolio achieved the licensing of 20 novel drugs and six new drug classes across its various investments. Following the trust's management transition to Schroders Capital in late 2023, the platform committed £10 million to private equity funds focused on early-stage biotech companies. Poszepczynski's background centers on healthcare venture capital, mergers and acquisitions trends, and risk management across the biotechnology sector from venture-stage startups to mega-cap public companies.